title: Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial".
authors.forename: David M
authors.initials: DM
authors.lastname: Marks
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Abramowitz
authors.forename: Glen I
authors.initials: GI
authors.lastname: Spielmans
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000928:Antidepressive Agents; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic